利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.012 秒)

    DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS
    2.
    发明申请
    DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS 失效

    公开(公告)号：US20070021426A1

    公开(公告)日：2007-01-25

    申请号：US11464355

    申请日：2006-08-14

    申请人： Ahmed ABOUABDELLAH ,  Regine BARTSCH-LI ,  Christian HOORNAERT ,  Antoine RAVET

    发明人： Ahmed ABOUABDELLAH ,  Regine BARTSCH-LI ,  Christian HOORNAERT ,  Antoine RAVET

    IPC分类号： A61K31/505 ,  A61K31/50 ,  A61K31/4965 ,  A61K31/47 ,  A61K31/325 ,  A61K31/4245 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/4164

    CPC分类号： C07D213/54 ,  C07C271/12 ,  C07D209/08 ,  C07D213/40 ,  C07D215/04 ,  C07D215/12 ,  C07D215/227 ,  C07D217/14 ,  C07D231/12 ,  C07D233/64 ,  C07D235/06 ,  C07D239/26 ,  C07D239/42 ,  C07D261/14 ,  C07D273/02 ,  C07D413/04 ,  C07D471/04

    摘要： The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ishaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula wherein A is selected from the group comprising X, Y or Z, and; X represents a methylene group optionally substituted by one or two C1-6-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkylene groups; Y represents either a C2-alkenylene group optionally substituted by one or two C1-6-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkylene groups; or a C2-alkynylene group; Z represents a group of formula:  m represents an integer ranging from 1 to 5; p and q represent integers and are defined such that p+q is a number ranging from 1 to 5; n represents an integer ranging from 1 to 7; R1 represents an R2 group optionally substituted by one or more R3 and/or R4 groups; R2 represents a group chosen from a pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, naphthyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 2-oxo-3,4-dihydroquinolinyl, 1-oxo-3,4-dihydroisoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl, naphthyridinyl, benzofuranyl, dihydrobenzofuranyl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, indazolyl, isoinR5R6, —O—(C1-3-alkylene)-O— or phenyl groups, the phenyl group optionally being substituted by one or more halogen atoms; R3 represents a group chosen from halogen atoms or cyano, nitro, C1-6-alkyl, C3-7-cycloalkyl, C1-6-alkoxy, hydroxyl, C1-6-thioalkyl, C1-6-fluoroalkyl, C1-6-fluoroalkoxy, C1-6-fluorothioalkyl, NR5R6, NR5COR6, NR5CO2R6, NR5SO2R6, COR5, CO2R5, CONR5R6, SO2R5, SO2N. R4 represents a group chosen from phenyl, phenyloxy, benzyloxy, naphthyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl groups; it being possible for the R4 group or groups to be substituted by one or more R3 groups which are identical to or different from one another; R5 and R6 represent, independently of one another, a hydrogen atom or a C1-6-alkyl group or form, with the atom or atoms which carry them, a ring chosen from an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine or piperazine ring, this ring optionally being substituted by a C1-6-alkyl or benzyl group; R7 represents a hydrogen atom or a C1-6-alkyl group, and R8 represents a hydrogen atom or a C1-6-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkylene group; a salt thereof, or a hydrate or a solvate of said compound or said salt.